May New Products and Industry News
- 0 Comments
- 2605 reads
In-vitro Study Data Show Wound Dressing With Silver Kills MRSA and Other Antibiotic Resistant Infections
ConvaTec (Skillman, NJ) released new in-vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly resistant bacteria. The study showed that bacteria found beneath the dressing died within 48 hours. The study results were presented at the 24th Annual SAWC/WHS in Dallas, Texas.
A simulated wound fluid (serum and peptone water) model was designed to measure antimicrobial activity over a 7-day wear time. A sample of the silver-containing sodium carboxymethyl cellulose wound dressing was aseptically transferred to the simulated wound fluid containing 1 x 106 cfu/mL of a wound pathogen (A baumannii, C difficile, CA-MRSA, or ESBL-producing bacteria). Following incubation, total viable counts (TVCs) were performed on each test model using a pour plate method. TVCs were performed on each model at 4, 24, 48, 72, and 96 hours, and at 7 days. All models were re-inoculated with a fresh challenge of the same bacteria at 72 hours. In the study, bacteria samples were covered with silver-containing sodium carboxymethyl cellulose wound dressing. The dressing was shown to be effective against emerging pathogens over a 7-day period, including against re-inoculation.
Visit www.convatec.com for more information.
MiMedx Group Launches EpiFix™ and announces Wound Care Division’s new Vice President
MiMedx Group Inc (Marietta, GA) has nationally launched their latest product, EpiFix™, a biologic implant specifically processed to offer a wide variety of wound healing and wound care options. The company also recently hired Frank Burrows as its Vice President of Wound Care. EpiFix is the wound care branded tissue resulting from the company’s proprietary Purion® process. The amniotic tissue produced using the process has generated a growing demand for easy to use, minimally manipulated allografts and has experienced increased growth in the areas of ophthalmology, dental, spine and sports medicine. The company’s tissues have been used in over 30,000 implants to date. Frank Burrows joins the company in the newly created capacity of Vice President of Wound Care. Frank brings to more than 20 years of experience and expertise in developing and implementing sales and marketing programs that have created growth for numerous medical devices and pharmaceuticals in the areas of wound closure, wound healing, tissue engineering, and bio-active therapeutics. Frank’s expertise and in-depth command of the wound care, wound healing, and tissue markets was gained through key roles at J & J Wound Management, Smith & Nephew, Advanced Tissue Sciences, and Histogen Aesthetics.
Visit www.mimedx.com for more information.